About

MAHTA since 2009

MAHTA Sp. z o. o. was established in 2009, when the legal framework for reimbursement processes based on EBM and HTA in Poland was beginning to emerge. Our team, with its experience and skills, had a huge impact on shaping the reimbursement documentation in this crucial period for HTA.

The essence of our work is to provide high-quality, evidence-based studies necessary to make responsible and rational decisions on the financing of medical technologies within the health care system, thus enabling access to modern therapies that prolong patients' lives and positively impact their quality of life. In our work, we combine knowledge and many years of experience in the area of Market-Access (MA) with Health Technology Assessment (HTA). The name of our company reflects the essence of the interaction between these two areas.

Dynamic development on the Polish market, successfully conducted processes ending in reimbursement decisions issued, as well as the demand of our clients for comprehensive global services, naturally led to MAHTA's involvement in international projects, which was the impulse for the creation of MAHTA Intl., whose core business is servicing foreign markets. Our experience, competence and extensive network of global partners allow us to carry out demanding and customised projects tailored to the needs of our clients in diverse markets.

Main area of activity

MAHTA's core business is the delivery of customised pharmaco-economic studies for our clients, ranging from initial appraisals (rapid review, feasibility study), through adaptations and audits of analyses carried out by other entities, preparation of scientific articles for renowned medical journals, to full HTA reports (de novo) and systemic studies. Our offer is aimed at pharmaceutical companies and healthcare decision-makers, as well as expert groups, scientific institutions and patient organisations. Our studies are prepared in Polish and English. The analyses we prepare (except when there is no need) are in compliance with the current provisions of legal acts and specific regulations in the area of HTA both in Poland and abroad. We are a trusted partner for our clients, resulting in many years of successful cooperation.

We support our clients at all stages of the reimbursement process, starting with the development of a reimbursement strategy, preparation of full reimbursement documentation, including the HTA report and a proposal for a risk-sharing mechanism, through the submission of a reimbursement application, to the preparation of the applicant for negotiations with the Economic Commission and the Minister of Health. Very often, we personally participate in meetings with various stakeholders in the decision-making process, i.e. the AOTMiT analytical team, the Economic Commission at the Ministry of Health and the Minister of Health himself.

MAHTA is about people

MAHTA is first and foremost about people who are dedicated to their work and constantly improving their knowledge, skills and competence. The core of the company consists of specialists in medicine, pharmacy, public health, biology, mathematics, statistics, economic modelling and IT programming. Thanks to our experience working alongside both pharmaceutical companies and decision-makers in the reimbursement process with analytical, statistical and mathematical competence and knowledge, we are able to meet the expectations of each of the parties as to the scope and presentation of evidence that is the basis for reimbursement decisions in Poland. 

This allows us to develop reimbursement strategies, create analyses and economic models based on EBM principles that comprehensively reflect the benefits of the assessed medical technologies in real clinical practice.

MAHTA's team is currently made up of more than 30 people, most of whom have worked with us almost since the company's inception. We pride ourselves on having a very low staff turnover, which allows us to effectively deepen our competencies rather than acquire them anew, allowing us to ensure the highest quality of our assignments.

Aware of the responsibility we bear, we always put the quality and reliability of our work first. We believe that by doing so, we can influence the availability of medicines on the market.

We are convinced that our work has a real impact on improving the quality of healthcare by, among other things, increasing the availability of therapies that save patients' lives and improve their quality of life.